News

Activation Capital Launches Start-the-Journey: Pre-Accelerator Program

Activation Capital proudly announces the launch of Start-the-Journey, a new BioHealth Pre-Accelerator designed to equip early-stage biotech and life science entrepreneurs with the knowledge and tools to build successful startups. Powered by Fat Robin Consulting, this innovative program supports founders in the initial phases of their entrepreneurial journey, preparing them for more advanced initiatives like Activation Capital’s Frontier BioHealth, launched earlier this year to support scaling advanced-stage startups.

The launch of Start-the-Journey comes as Central Virginia’s biotech and life sciences sector continues to thrive. The region has experienced significant advancements, including the growth of its pharmaceutical manufacturing cluster and an expansion of biotech educational programs at local universities. With local research institutions expanding their biotech offerings, Central Virginia is becoming a recognized hub for life sciences innovation. Activation Capital is committed to supporting this ecosystem by helping early-stage entrepreneurs build a solid foundation through Start-the-Journey and its later-stage program Frontier BioHealth.

“This program provides a foundational experience for entrepreneurs navigating the early challenges of building a biohealth startup. Our goal is to help them develop the essential skills needed to succeed,” said Dr. Jim Pannucci, Vice President of Entrepreneurship at Activation Capital.

The program, with content provided by Fat Robin Consulting, includes a personalized intake session for each startup, offering tailored guidance from experts. Cohorts will operate on a rolling model, starting monthly from October 2024 through January 2025. Participants will cover critical topics such as entrepreneurial qualities, market value creation, MVP development, and key resources for entrepreneurs.

Seema Sood, CEO and Founder of Fat Robin Consulting, expressed enthusiasm for the program: “We’re excited to work with founders who are shaping the future of biotech. A strong foundation on entrepreneurship will scaffold the long-term success of young companies.”

Start-the-Journey is ideal for founders in Richmond, across Virginia, or those considering locating their company in the state, with a focus on deep-tech biotechnology, pharmaceuticals, medical devices, and diagnostics. Offered at no cost, the program is designed to reduce financial burdens for early-stage entrepreneurs, and Activation Capital takes no founder equity.

“We’re excited about the potential impact Start-the-Journey will have in fostering innovation and accelerating the growth of Virginia’s BioHealth sector,” Pannucci added. Additional information can be found at https://activation.capital/start-the-journey/.

Start-the-Journey is funded in part through a grant with the U.S. Small Business Administration (SBA). All opinions, conclusions, and/or recommendations expressed herein are those of Activation Capital and do not necessarily reflect the views of the SBA.

Learn more here.

Recent News

02/03/2026

SSI Diagnostica Group Acquires InDevR

SSI Diagnostica Group, a global company specializing in testing solutions for infectious diseases, has announced the acquisition of InDevR, a Colorado-based provider of advanced multiplexed solutions for vaccine testing and quality control. The addition strengthens SSID Group’s leadership in pneumococcal vaccine QC testing with next-generation multiplexing assays and enhanced customization capabilities. InDevR will advance the Group’s offering by

02/02/2026

Accorto Regulatory Solutions Launches Dedicated Quality & Compliance Division

Accorto Regulatory Solutions, LLC (Accorto), a U.S.-based regulatory advisory firm, announced the launch of its dedicated Quality & Compliance Division, expanding the firm’s ability to deliver integrated regulatory and compliance support to organizations involved in the development of FDA-regulated products. The new division formalizes and expands Accorto’s compliance and GxP services in response to growing

01/29/2026

NIRSense, Inc. & Aspen Medical USA (AMUSA): Strengthening Frontline Medicine: U.S.–Developed Tissue Oxygenation Technology Delivered to Ukraine

NIRSense and Aspen Medical USA (AMUSA) are pleased to announce the donation of 12 portable tissue-ischemia monitoring kits (comprising advanced sensor consoles plus tablets) to the Ministry of Defence of Ukraine (MoD) for deployment in frontline Role-1 and Role-2 casualty care facilities in Ukraine. These investigational prototype systems are provided for use by military medical